Research Paper Volume 15, Issue 17 pp 8744—8769
Comprehensive analysis and experimental validation reveal elevated CLCN4 is a promising biomarker in endometrial cancer
Figure 10. The expression and mutation of CLCN4. (A) Differential expression of CLCN4 in endometrial cancer and normal tissues (***p < 0.001). (B) The mutation of CLCN4 and the distribution of protein domains in the labeled hot lollipop graph. (C) Waterfall charts show different somatic mutation of several cancers in the CLCN4 high and low expression group.